Dr. Terence J. McLaughlin, MD

Dr. McLaughlin practices at Strong Memorial Hospital in Rochester, New York, part of University of Rochester Medical Center.

Dr. McLaughlin's NPI, 1497288393, was assigned on April 6, 2017. Dr. McLaughlin graduated from University at Buffalo School of Medicine in 2017. Dr. McLaughlin holds New York license 323552.

Dr. McLaughlin's primary practice is Strong Memorial Hospital, at 601 Elmwood Ave, Rochester, NY 14642 in Monroe County. The practice phone is (585) 275-2121.

Dr. McLaughlin's primary practice is Strong Memorial Hospital in Rochester, New York, part of University of Rochester Medical Center. Dr. McLaughlin is also affiliated with Highland Hospital. The medical group on file is URMC Cardiology. Dmand AI also links Dr. McLaughlin to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McLaughlin practices, 7 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. McLaughlin's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. McLaughlin is licensed in New York.

CMS data shows 881 Medicare services from Dr. McLaughlin across 14 procedure codes in 2024, for 549 Medicare patients. Medicare paid $32,060 for them.

CMS counts 549 Medicare patients who saw Dr. McLaughlin in 2024. The largest group is 65 to 74, with 203 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 32% are also on Medicaid. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McLaughlin's median patient age at 66, with 48% women.

In 2024, Dr. McLaughlin wrote 2,296 Medicare Part D claims for 571 patients. 86% of them were for generic drugs. CMS names the drug for 2,128 of them, across 30 drugs with 11 or more claims each, at $394,399 in total drug cost. In 2023, CMS named 51 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. McLaughlin for performance year 2024, reported as part of a group. Dr. McLaughlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. McLaughlin as offering telehealth.

Dmand AI links 5 papers to Dr. McLaughlin, published from 2012 to 2021. 2019 was the busiest year, with 2. The most frequent topics are Cardiomyopathies and Defibrillators, Implantable. Dr. McLaughlin's most frequent co-authors are Samir F. Saba, Sandeep Jain, MD and Sandeep Jain, MD.

CMS Open Payments shows 2 general payments to Dr. McLaughlin from 2 drug and device companies in 2025. Food and beverage make up the largest share, 100% of the total. Eli Lilly and Company paid the most, $115.

Dr. McLaughlin graduated from University at Buffalo School of Medicine in 2017.